Drug Safety

, Volume 30, Issue 8, pp 705–713 | Cite as

Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation

  • Catherine B. Johannes
  • Najat Ziyadeh
  • John D. Seeger
  • Ed Tucker
  • Christoph Reiter
  • Gerald Faich
Original Research Article


Background: Data on the incidence of serious allergic reactions to fluoroquinolone antibacterials are mainly derived from spontaneous reports that cannot be used to accurately estimate incidence.

Methods: This study estimated the drug-specific incidence of serious allergic reactions after fluoroquinolone, cephalosporin and phenoxymethylpenicillin potassium exposure, using claims for healthcare services with confirmation through medical record abstraction within a large health insurer database. Cohorts exposed to each antibacterial of interest (moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin, cephalosporins and penicillin) were identified, and followed for 14 days for anaphylaxis (9th revision of the International Classification of Diseases [ICD-9] code 995.0), other allergic drug reactions (ICD-9 995.2, 995.3) or cardiopulmonary resuscitation.

Results: The incidence per 10 000 first dispensings of any allergic diagnosis made in the hospital or emergency department was similar for moxifloxacin (4.3; 95% CI 3.5, 5.3), penicillin (4.7; 95% CI 3.8, 5.7) and ciprofloxacin (5.4; 95% CI 4.4, 6.5). The incidence for moxifloxacin was lower than that for levofloxacin (8.7; 95% CI 7.4, 10.0), gatifloxacin (6.7; 95% CI 5.6, 7.9) and the cephalosporins (7.5; 95% CI 6.3, 8.8). The incidence of anaphylaxis/anaphylactoid reactions after first dispensings was similar for the fluoroquinolones: 0.1 (95% CI 0.0, 0.3) for ciprofloxacin, 0.3 (95% CI 0.1, 0.5) for moxifloxacin, 0.3 (95% CI 0.1, 0.6) for gatifloxacin and 0.5 (95% CI 0.3, 0.9) for levofloxacin; and comparable with that of the cephalosporins (0.2; 95% CI 0.0, 0.4) and penicillin (0.1; 95% CI 0.0, 0.3).

Conclusions: Anaphylactic reactions were rare and their incidence did not differ substantially among the drug groups studied. By determining the occurrence of reactions following defined exposures, these results provide a context for the interpretation of spontaneous reports of allergic reactions.


  1. 1.
    Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798–817PubMedCrossRefGoogle Scholar
  2. 2.
    Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940–50PubMedCrossRefGoogle Scholar
  3. 3.
    Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opinion Allergy Immunol 2003; 3: 275–81CrossRefGoogle Scholar
  4. 4.
    Lieberman PL. Chapter 83: Anaphylaxis and anaphylactoid reactions. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton’s allergy: principles and practice. 6th ed. St Louis (MO): Mosby, Inc., 2003Google Scholar
  5. 5.
    Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005Google Scholar
  6. 6.
    Muelleman RL, Tran TP. Chapter 113: Allergy, hypersensitivity, and anaphylaxis. In: Rosen’s emergency medicine: concepts and clinical practice. 5th ed. St Louis (MO): Mosby, Inc., 2002Google Scholar
  7. 7.
    Smythe MA, Cappelletty DM. Anaphylactoid reaction to levofloxacin. Pharmacotherapy 2000; 20: 1520–3PubMedCrossRefGoogle Scholar
  8. 8.
    Ho DY, Song JC, Wang CC. Anaphylactoid reaction to ciprofloxacin. Ann Pharmacother 2003; 37: 1018–23PubMedCrossRefGoogle Scholar
  9. 9.
    Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 1995; 95: 637–8PubMedCrossRefGoogle Scholar
  10. 10.
    Brown AFT, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861–6PubMedCrossRefGoogle Scholar
  11. 11.
    Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253–72SCrossRefGoogle Scholar
  12. 12.
    Assouad M, Willcourt RJ, Goodman PH. Anaphylactoid reactions to ciprofloxacin. Ann Internal Med 1995; 122: 396–7Google Scholar
  13. 13.
    Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29(11): 1087–100PubMedCrossRefGoogle Scholar
  14. 14.
    Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041–3PubMedGoogle Scholar
  15. 15.
    Alemán AM, Quirce S, Cuesta J, et al. Anaphylactoid reaction caused by moxifloxacin. J Invest Allergol Clin Immunol 2002; 12: 67–8Google Scholar
  16. 16.
    Rothman KJ. Epidemiology an introduction. New York: Oxford University Press, 2000: 134Google Scholar
  17. 17.
    Gilman AG, Goodman LS, Rall TW, Murad F. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 1135Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Catherine B. Johannes
    • 1
    • 2
  • Najat Ziyadeh
    • 1
  • John D. Seeger
    • 1
    • 3
  • Ed Tucker
    • 4
  • Christoph Reiter
    • 5
  • Gerald Faich
    • 6
  1. 1.i3 Drug SafetyWalthamUSA
  2. 2.RTI Health SolutionsWalthamUSA
  3. 3.Department of EpidemiologyHarvard School of Public HealthBostonUSA
  4. 4.Bayer Healthcare, Bayer Pharmaceuticals CorporationWest HavenUSA
  5. 5.Bayer Healthcare AGLeverkusenGermany
  6. 6.United Biosource CorporationAmblerUSA

Personalised recommendations